SecBot SecBot
8-K ·Filed Nov 9, 2026

AXGN

Axogen, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed7d 18h ago SEC0000805928-26-000110
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

Monitor for initial revenue contribution from prostate procedures in upcoming quarterly filings. The launch represents a significant market expansion beyond Axogen's current peripheral nerve repair business, but adoption depends on surgeon training, reimbursement, and clinical validation.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$50.64
T+0 close · Nov 9, 2026 · via day close
Latest settled
+9.36%
T+5 · $55.38
Vs SPY
+11.05%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $50.64entry
  2. T+1 · 7d ago +0.49%α +0.86% · $50.89
  3. T+5 · 20h ago +9.36%α +11.05% · $55.38
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axogen hosted an investor event announcing its decision to launch into the prostate nerve reconstruction market using its Avance nerve allograft. The presentation cited a $754 million total addressable market and clinical data showing improved erectile function recovery versus historical controls. No financial results or guidance were provided.

Key Facts

  • Axogen announced a decision to launch into the prostate nerve reconstruction market
  • Total addressable market estimated at $754 million with a weighted ASP of ~$7,000 per procedure
  • Clinical data from 117 patients with at least 6 months follow-up showed ~80% had better than expected erectile function and >95% return of continence
  • Over 220 patients have been reconstructed with Avance nerve allograft in prostate procedures
  • Patient survey data indicated 88% would ask their surgeon about nerve reconstruction and 87% would switch surgeons
  • Hospital administrator survey showed 80% said meaningful improvement in ED recovery can justify pre-coverage adoption

Financial Impact

New market opportunity with $754 million TAM and ~$7,000 weighted ASP per procedure

revenue

Risk Factors

  • Reimbursement pathway is not established; 56% of hospital administrators would support adoption before broad coverage
  • Clinical data is based on a relatively small sample (117 patients with 6-month follow-up) and historical controls
  • Surgeon adoption and training are required for a technically demanding robotic procedure
  • Forward-looking statements with no guarantee of market acceptance or commercial success

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000805928-26-000110
Document: prostatecall11926deckfin.htm0000805928-26-000110
Document: 0000805928-26-000110-index-headers.html0000805928-26-000110
Document: 0000805928-26-000110-index.html0000805928-26-000110
Document: 0000805928-26-000110.txt0000805928-26-000110

Track record

19 reports on AXGN

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +32.04% at T+20 after the Oct 1, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $55.78 Now $55.38 +0.72% settles Dec 15
  2. Nov 9, 20267d ago 8-K Bullish 5/10 Viewing Entry $50.64 Now $55.38 +9.36% settles Dec 8
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $51.35 Now $55.38 +7.85% settles Dec 3
  4. Oct 28, 202619d ago 8-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $49.25 Now $55.38 +12.45% settles Nov 25
  6. Oct 2, 20266w ago SC 13G Neutral 4/10 Entry $37.22 to $49.37 Now $55.38 +48.79% ▲ +32.64% +35.11% vs SPY
  7. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $37.39 to $49.37 Now $55.38 +48.11% ▲ +32.04% +33.85% vs SPY
  8. Oct 1, 20266w ago Press Release Bullish 6/10 Entry $37.39 to $49.37 Now $55.38 +48.11% ▲ +32.04% +33.85% vs SPY
  9. Sep 10, 20269w ago 424B5 Mixed 6/10 Entry $42.16 to $36.13 Now $55.38 +31.36% ▼ −14.30% −16.17% vs SPY
  10. Sep 10, 20269w ago 8-K Bullish 7/10 Entry $41.85 to $36.18 Now $55.38 +32.33% ▼ −13.55% −15.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026